Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages

Kwon, Junki; Sung, Kyung Rim

doi:10.1155/2017/7672485

Cited by 24 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However the effect of anti-VEGF drug may be transient, hence repeated injections are sometimes required. Additionally, Kwon et al demonstrated pre-operative injection of anti-VEGF drugs increases the success rate of AGV implantation when peripheral anterior synechiae is less than ½ 29. Our study concluded similarly that preoperative anti-VEGF therapy was not associated with a better surgical success at 1 year after drainage valve implantation.…”

Section: Discussionsupporting

confidence: 75%

Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma

Xie

Hai²,

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

To evaluate the efficacy of Ahmed glaucoma valve (AGV) implantation in treating neovascular glaucoma (NVG) and analyze the factors influencing the surgical success rate, a retrospective investigation of 59 NVG patients (66 eyes) who underwent AGV implantation was conducted at Jiangsu Province Hospital, China, from January 2014 to June 2018. Intraocular pressure (IOP), visual acuity, surgical success rates, medications, and complications were monitored at post-operative 1 day, 1 week, 1, 3, 6 and 12 months. Surgical success criteria were defined as 6 mm Hg < IOP < 21 mmHg with or without additional medications. Results showed average IOP was statistically significant between pre-operative visit and each follow-up visit (all P<0.05). At 12 months, the success rate was 66.7%. Multiple stepwise regression analysis suggested that age, panretinal photocoagulation (PRP), complications and hyphema were significant factors influencing the surgical success rate (all P<0.05). Thus, we conclude that AGV implantation is effective and safe for treatment of NVG. Surgical success is dependent on age, PRP, complications, and hyphema.

show abstract

Section: Discussionsupporting

confidence: 75%

Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma

Xie

Hai²,

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Recently, intraocular injection of anti-VEGF has been to treat retinal ischemia. Intravitreal anti-VEGF injection in NVG patients could improve the prognosis of AGV implantation [ 17 18 19 20 ]. Our subgroup analysis of NVG patients also found that pre-AGV or concurrent intracameral anti-VEFG injection was predictive of surgical success.…”

Section: Discussionmentioning

confidence: 99%

Influence of Vitrectomy-related Factors on the Outcome of Ahmed Glaucoma Valve Implantation

Sung

Kim

2018

Korean J Ophthalmol

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate the outcome of Ahmed glaucoma valve (AGV) implantation in eyes with refractory secondary glaucoma following pars plana vitrectomy (PPV) and the associated prognostic factors.MethodsA total of 146 eyes in 146 patients who underwent AGV implantation after PPV (followed up for ≥1 year) were included. AGV implantation was considered successful when the intraocular pressure (IOP) was 6 to 21 mmHg regardless of using IOP-lowering medication. The hazard ratios (HRs) associated with surgical failure were determined with Cox proportional analysis.ResultsThe most common cause for PPV was complications of proliferative diabetic retinopathy (50%). The mean and peak IOPs between PPV and AGV implantation were 26.9 ± 6.6 and 35.9 ± 10.2 mmHg, respectively. AGV implantation was performed on average 18.7 months after PPV, and its overall success rate was 80.1% during a mean follow-up period of 43.6 months. In multivariate analyses, rubeosis observed before AGV implantation (HR, 4.07; 95% confidence interval, 1.57 to 10.6; p = 0.004) and higher peak IOP before AGV (HR, 1.04; 95% confidence interval, 1.00 to 1.07; p = 0.034) were predictive of failure. However, no PPV-related factors were associated with the surgical outcome of AGV implantation.ConclusionsThe outcome of AGV implantation is good in refractory glaucoma following PPV. Rubeosis after PPV and higher peak IOP before AGV are risk factors for poor outcomes. Patients who undergo PPV should be followed for the development of rubeosis and IOP control.

show abstract

“…One of the 2 most common causes of NVG is CRVO [1][2][3][4][5][6] . NVG does not develop in non-ischemic CRVO.…”

Section: Etiologymentioning

confidence: 99%

Neovascular Glaucoma – A Review

Filik¹

2020

jamp

View full text Add to dashboard Cite

Neovascular glaucoma (NVG) is a severely blinding disease with high intraocular pressure (IOP) resistant to treatment. The main problem in NVG is the release of vascular endothelial growth factor (VEGF) due to retinal ischemia caused by the underlying disease. Both the underlying disease and intraocular pressure should be treated in management of patients with NVG. The purpose of this review is to discuss etiology, pathogenesis, clinic classification and management of NVG. The main purpose in NVG management is to prevent the development of NVG by treating the underlying cause mainly proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO) and ocular ischemic syndrome (OIS). If NVG has developed, then it will be necessary to both treat the underlying etiology and high intraocular pressure. Panretinal photocoagulation (PRP) and anti-VEGF drugs are important in the treatment of NVG. Anti-glaucomatous drugs that reduce the production of aqueous are used in medical treatment in the control of IOP. Medical treatment may be insufficient in the control of IOP. Surgical methods will b e required when IOP is not controlled by medical therapy. Fibrosis that develop after trabeculectomy and tube shunt surgeries reduces the success of surgery. Applying preoperative anti-VEGF may increase the rate of surgical success. Cyclodestructive procedures should be preferred when other surgical methods fail and patients with poor visual prognosis.

show abstract

Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages

Cited by 24 publications

References 21 publications

Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma

Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma

Influence of Vitrectomy-related Factors on the Outcome of Ahmed Glaucoma Valve Implantation

Neovascular Glaucoma – A Review

Contact Info

Product

Resources

About